---
title: "Poster download: Tumor organoid and immune cells co-cultures to study myeloid cells-targeting immunotherapy"
description: "Download our poster presented at AACR 2024: Tumor organoid and immune cells co-cultures to study myeloid cells-targeting immunotherapy"
image: https://resources.huborganoids.nl/hubfs/social-media-poster-2696.jpg
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

PRESENTED AT AACR 2024

# Tumor organoid and immune cells co-cultures to study myeloid cells-targeting immunotherapy

![AACR 2024 Poster](https://resources.huborganoids.nl/hs-fs/hubfs/assets2023/2696.jpg?width=300&name=2696.jpg)

Cancer immunotherapy is one of the main pillars of oncology treatment, due to the clinical success of therapies aimed at enhancing anti-tumoral T-cell responses. Nonetheless, many patients do not benefit from these approaches, highlighting the need to develop novel immunomodulatory strategies. Exploiting the anti-tumor capacity of innate immune cells is a promising approach that can overcome specific limitations of T cell-targeting therapies. Still, promising therapeutic developments face hurdles in translating preclinical findings into treatment since conventional 2D cancer models hold low clinical predictive value. HUB developed an innovative alternative, building on the discovery that adult stem cells proliferate and organize into three-dimensional organotypic structures. Patient-derived organoids (PDO) are generated from healthy and diseased tissues and recapitulate complex characteristics of the original parental tissue, including molecular heterogeneity and morphological and functional traits. To assess the efficacy of therapies that engage innate immune cells, we developed an assay in which organoids derived from colorectal (CRC) or breast cancer patients were co-cultured with PBMC-derived macrophages or monocytes to evaluate the activity and cytotoxic potential of exogenously activated myeloid cells.

#### Download this poster to discover:

- The establishment of organoid-based co-culture platform with PBMC-derived macrophages or monocytes
- The development of the ADCP phagocytosis assay to evaluate the cytotoxic potential of exogenously activated myeloid cells
- The data demonstrating the activation of monocytes and tumor organoid phagocytosis in a CRC or breast PDOs co-cultured with PBMC-derived monocytes

### Download our poster

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*